Adial Pharmaceuticals WT Performance
| ADILWDelisted Stock | USD 0.01 0 52.50% |
The firm shows a Beta (market volatility) of -0.99, which signifies possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Adial Pharmaceuticals are expected to decrease slowly. On the other hand, during market turmoil, Adial Pharmaceuticals is expected to outperform it slightly. Adial Pharmaceuticals right now shows a risk of 0.0%. Please confirm Adial Pharmaceuticals total risk alpha and the relationship between the potential upside and day typical price , to decide if Adial Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Adial Pharmaceuticals WT has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable essential indicators, Adial Pharmaceuticals is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
| Begin Period Cash Flow | 6.1 M | |
| Free Cash Flow | -11.2 M |
Adial |
Adial Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 0.61 in Adial Pharmaceuticals WT on August 28, 2024 and sell it today you would earn a total of 0.00 from holding Adial Pharmaceuticals WT or generate 0.0% return on investment over 90 days. Adial Pharmaceuticals WT is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded stocks are less volatile than Adial, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Adial Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Adial Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Adial Pharmaceuticals WT, and traders can use it to determine the average amount a Adial Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ADILW |
Based on monthly moving average Adial Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Adial Pharmaceuticals by adding Adial Pharmaceuticals to a well-diversified portfolio.
Adial Pharmaceuticals Fundamentals Growth
Adial Stock prices reflect investors' perceptions of the future prospects and financial health of Adial Pharmaceuticals, and Adial Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Adial Stock performance.
| EBITDA | (13.78 M) | |||
| Total Debt | 207.38 K | |||
| Cash Flow From Operations | (11.19 M) | |||
| Total Asset | 5.73 M | |||
| Retained Earnings | (63.67 M) | |||
About Adial Pharmaceuticals Performance
Evaluating Adial Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Adial Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Adial Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Adial Pharmaceuticals performance evaluation
Checking the ongoing alerts about Adial Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Adial Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Adial Pharmaceuticals is not yet fully synchronised with the market data | |
| Adial Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Adial Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (12.73 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Adial Pharmaceuticals generates negative cash flow from operations |
- Analyzing Adial Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Adial Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Adial Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Adial Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Adial Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Adial Pharmaceuticals' stock. These opinions can provide insight into Adial Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Adial Stock
If you are still planning to invest in Adial Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Adial Pharmaceuticals' history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |